about
Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancerDoes increased local bone resorption secondary to breast and prostate cancer result in increased cartilage degradation?Systemic radionuclide therapy in pain palliation.Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases.Bone health and prostate cancer.Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid.Zoledronate for metastatic bone disease and pain: a meta-analysis of randomized clinical trials.Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancerOsteoclast targeted therapy for prostate cancer: bisphosphonates and beyond.Biochemical markers of bone turnover and clinical outcomes in men with prostate cancerTargeting bone metabolism in patients with advanced prostate cancer: current options and controversies.Effect of neoadjuvant chemotherapy on the serum levels of bone turnover markers in women with early-stage breast cancerBony metastases: assessing response to therapy with whole-body diffusion MRI.Predictors of survival in prostate cancer patients with bone metastasis and extremely high prostate-specific antigen levelsBone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patientsValue of C-telopeptide-cross-linked Type I collagen, osteocalcin, bone-specific alkaline phosphatase and procollagen Type I N-terminal propeptide in the diagnosis and prognosis of bone metastasis in patients with malignant tumors.Macrophage inhibitory cytokine 1: a new prognostic marker in prostate cancer.Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluationCollagen crosslink excretion and staging of oral cancer.Follow-up of collagen crosslink excretion in patients with oral squamous cell carcinoma and analysis of tissue samples.Pilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patients with metastatic renal cell carcinoma.New and emerging therapies for bone metastases in genitourinary cancers.Emerging therapies to prevent skeletal morbidity in men with prostate cancer.Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancerSerum N-Terminal Propeptide of Collagen Type I is Associated with the Number of Bone Metastases in Breast and Prostate Cancer and Correlates to Other Bone Related Markers.Skeletal metastasis: treatments, mouse models, and the Wnt signaling.SEOM Clinical Guideline for bone metastases from solid tumours (2016).Horizon scanning for novel therapeutics for the treatment of prostate cancer.The current role of circulating tumor cells in the diagnosis and management of bone metastases in advanced prostate cancer.Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases.Quantitative pharmacology of denosumab in patients with bone metastases from solid tumors.Extracellular vesicles for personalized therapy decision support in advanced metastatic cancers and its potential impact for prostate cancer.Phagocytosis and remodeling of collagen matricesSerum alkaline phosphatase differentiates prostate-specific antigen flare from early disease progression after docetaxel chemotherapy in castration-resistant prostate cancer with bone metastasis.The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers.Bone metastases in patients with small cell lung carcinoma: rate of development, early versus late onset, modality of treatment, and their impact on survival. A single-institution retrospective cohort study.Therapy monitoring of skeletal metastases with whole-body diffusion MRI.Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases.[Diagnostic value of bone metabolic markers ICTP and BAP in lung cancer patients with bone metastases].Q57136184
P2860
Q27021268-B2E1059B-47EB-45E6-9B98-3021893493BDQ33347582-6D5E51E1-4259-4D7E-A22F-A3033F284E7EQ33369416-793038D7-9BF0-4FDE-BBEA-04BF77BF3639Q33441667-BC9548B8-AD05-4073-B223-D7352B2F1E08Q33977536-A67C3517-A77E-4766-9F3B-14742D386B4FQ34026943-58255B30-9C3B-428B-8975-3BE34D459FF8Q34320376-C7ECA867-D9B7-40AA-8A78-BEDC61F9B5C1Q34613941-83E4E415-BF0D-4F4D-8605-06DF997BC904Q34960635-262D5C08-1331-4D7E-8A4C-530BF4E9A7D1Q35022212-393B9435-D2F2-44B7-AF7C-397B1C8440EBQ35087364-8E8E9FB3-F209-4D2E-8337-66AD8604E147Q35553550-D463A788-7636-4A08-919D-B67FE96E26A9Q35697593-9D65D375-EC3B-4526-83F3-AC677CAB1FEFQ35827731-91E3A9C4-829E-44F2-A43D-07DEB91DAE6FQ36067835-BC7C2A04-FCF9-44FB-84AF-1DF4A5E323FCQ36516278-0F274690-B6C7-43CE-8441-0A765B62E2D7Q36570789-7D3A43B1-2395-45A6-ADF0-62429A0FB79CQ36612227-A76DDD00-4A8F-4BCC-A5FC-0796163A8F64Q36646700-6100D675-8728-4232-8558-14A22F587F3AQ36671503-74E29CBB-32C0-4983-B522-70AA812A045EQ36810618-D78996F4-4D96-4A24-A97D-D76A910D1AE9Q36866291-34F88E81-3182-44D4-A333-0CB915096528Q36910469-576E409F-D88C-45EF-95FA-FC38BBFC3E51Q37127044-58807BCF-629B-411D-9876-F869C8A06FA7Q37218904-77F49D40-AF8A-4A9D-A3DC-FD1DCF6F51F7Q37354085-589D920E-9A52-41C4-9586-679CE9619D4BQ37475161-27A7B0EF-C370-406A-BE34-17FD75E014D4Q37792060-3E12E100-F9BB-4E38-BB5C-BC1517A1F3D3Q37992696-25F7FB76-5D65-4865-9E18-5F9AECC470A8Q38004275-E58AEBB6-6675-48D9-AC1F-14F263EC87D1Q38364467-91676A54-9588-484E-8188-E7AD21097143Q38600919-A912D8EA-99C8-41BC-B306-DF4BA9800C7BQ41854776-02CDE6F7-2D3D-4BD2-A605-37B44C96685CQ45738696-B28B691E-2F5D-4203-B0C9-733BC2AF40CAQ46832072-5ABE1019-EC17-467E-A6B1-420E8E15E4B8Q48719655-6017B85D-B5F8-46BD-969B-0A4D50DAE339Q51114179-F3546169-DD68-4E9D-8FF8-21519739FD79Q53130858-DFFE3B7C-1079-4BB6-A0CF-EA01014CD06CQ55439077-89A5394D-DB36-4887-ADA9-D1824034031FQ57136184-1AD0A4CA-CC52-41DD-99EC-7AEDFCA3C39B
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Biochemical markers and skeletal metastases.
@ast
Biochemical markers and skeletal metastases.
@en
type
label
Biochemical markers and skeletal metastases.
@ast
Biochemical markers and skeletal metastases.
@en
prefLabel
Biochemical markers and skeletal metastases.
@ast
Biochemical markers and skeletal metastases.
@en
P2093
P2860
P1433
P1476
Biochemical markers and skeletal metastases.
@en
P2093
P2860
P304
P356
10.1002/1097-0142(20000615)88:12+<2919::AID-CNCR7>3.0.CO;2-Z
P407
P433
P577
2000-06-01T00:00:00Z